Is sustained remission over time, without the need for maintenance treatment, one of the differential benefits? 

Dr. Daniel Ginard

One of the differential benefits of this therapy is the fact that, when the patient has a complete response to the therapy, in the majority of cases, a maintenance treatment is not required. As I previously said, in some patients, we can indeed do maintenance treatment because effectiveness is lost, but most of them, and this is a differential fact, maintain it after finishing the induction treatment.

References:

• Iida T et al. Adsorptive Depletion of Myeloid Lineage Leucocytes as Remission Induction Therapy in Patients with Ulcerative Colitis after Failure of First-Line Medications: Results from a Three-Year Real World, Clinical Practice. Digestion. 2017;96(2):119-126.
• Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010 Jul 6;10:73.
• T Ljung, O Østergaard Thomsen, M Vatn, et al. :007Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: The first 100 patients treated in Scandinavia, Scand. J. Gastroenterol. 42:2, 221-227